Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.40 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 4/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949749 | 1.00 | ACE (0.40) | ACECASP3MMELCKCASP1 | |
| SCHEMBL10563773 | 0.93 | ACE (0.33) | ACECASP3MMEHDAC1HDAC8 | |
| SCHEMBL10565831 | 0.90 | ACE (0.44) | ACECASP3PARP1HSD17B10ROCK2 | |
| SCHEMBL10671600 | 0.86 | ACE (0.41) | ACECASP3MMELCKCASP1 | |
| SCHEMBL1490176 | 0.86 | ACE (0.40) | ACEMMELCKCASP1 | |
| SCHEMBL12443735 | 0.86 | CASP3 (0.39) | ACECASP3PARP1HSD17B10ROCK2 | |
| SCHEMBL10668095 | 0.82 | ACE (0.38) | ACECASP3MMELCKCASP1 | |
| SCHEMBL949486 | 0.82 | CASP3 (0.39) | CASP3PARP1HSD17B10ROCK2NPC1 | |
| SCHEMBL949485 | 0.82 | CASP3 (0.39) | CASP3PARP1HSD17B10ROCK2NPC1 | |
| SCHEMBL10201273 | 0.82 | CASP3 (0.38) | ACECASP3PARP1HSD17B10ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2791161-B1 | INHIBITORS OF HCV NS5A | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-9180193-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9133170-B2 | Inhibitors of HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HOFFMANN-LA ROCHE INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20140255344-A1 | Antiviral Compounds | Hiffmann-La Roche Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20120328565-A1 | ANTIVIRAL COMPOUNDS | BRINKMAN JOHN A (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | ALAM MUZAFFAR (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-6423840-B1 | FORMING N-ACYLAMINO COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-23 | — | — | US | disclosed |
| US-6420522-B1 | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-16 | — | — | US | disclosed |
| US-6258948-B1 | AN N-ACYLAMINO COMPOUND; ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED | 2001-07-10 | — | — | US | disclosed |
| US-6204261-B1 | Inhibitors of interleukin-1β Converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-03-20 | — | — | US | disclosed |
| US-6103711-A | INTERLEUKIN-1 MEDIATED DISEASES; ANTIINFLAMMATORY AND -CARCINOGENIC AGENTS; AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-08-15 | — | — | US | disclosed |
| US-6008217-A | AN ENZYME INHIBITOR AGAINST INTERLEUKIN-1B, FOR TREATING APOPTOSIS-MEDIATED DISEASES, INCLUDING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, PROLIFERATIVE DISORDERS, INFECTIOUS DISEASES, AND DEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-28 | — | — | US | disclosed |
| US-5973111-A | NOVEL COMPOUNDS THAT ARE CAPABLE OF BINDING TO THE ACTIVE SITE OF INTERLEUKIN-1B-CONVERTING ENZYME (ICE) AND INHIBITING ACTIVITY OF THAT ENZYME; ADMINISTERING TO TREAT INFLAMMATORY, AUTOIMMUNE, AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | ACE 16/4885CASP3 85/4885MME 279/4885 |
| US-20120328565-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, HAVCR2, MAVS | ACE 104/4885CASP3 1970/4885MME 1409/4885 |
| US-20120230951-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ACE 79/4885CASP3 634/4885MME 503/4885 |
| US-20140255344-A1 | Antiviral Compounds | EIF2AK2, HAVCR2, MAVS | ACE 80/4885CASP3 1485/4885MME 640/4885 |
| US-20150166514-A1 | INHIBITORS OF HCV NS5A | HAVCR2, EIF2AK2, MAVS | ACE 1102/4885CASP3 4006/4885MME 729/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | ACE 6/4885CASP3 542/4885MME 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.